Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 397 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New ESMO President 2029-2030 Elected June 3, 2026 Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable... October 5, 2026 High School Holds Early Graduation Ceremony For Teen With Terminal Cancer November 28, 2021 What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Load more HOT NEWS What’s Your Mantra? Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS... Forging Military Partnerships to Empower the Cancer Research Enterprise An existing blood test for ovarian cancer has been re-evaluated. The...
